Ligand Enters into OmniAb Platform License with Surface Oncology

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with its OmniAb Platform License with Surface Oncology for human antibody discovery using transgenic rodents. Under the license, Ligand will be eligible to receive annual platform access payments, development and regulatory milestone payments, and tiered royalties for each product incorporating an OmniAb antibod.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Surface Oncology is an mmune-oncology company developing next-generation immunotherapies targeting the tumor microenvironment.